Sign up
Pharma Capital
Why invest in VPT?
Big Picture

VentriPoint Diagnostics' heart monitoring tech further boosted by agreement with Canadian government

The goal of the program is to extend the visualization extracted from 2D ultrasound images and visualize 4D images
1542204301_heart.jpg
BigPicture
VentriPoint's technology is aimed at identifying heart problems early on

VentriPoint Diagnostics Ltd (CVE:VPT) unveiled another boost for its technology  - an agreement with the Government of Canada to develop further its heart monitoring system.

The National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) will provide advisory support and conditional funding to share costs of a project designed to accelerate the company's VMS+ system's next-generation product.

READ: VentriPoint Diagnostics receives order for its VMS Plus - from leading cardiac hospital in Toronto

The goal is to extend the visualization extracted from 2D ultrasound images of the heart to construct and visualize 4D images.

"Currently, 4D products are available in the marketplace and while they have improved significantly, they still are only able to get useable images in 60% of people for the basic heart analysis and, therefore, are only used for research purposes," said Ventripoint in a statement.

Ventripoint's heart analysis machine provides medics with a more efficient and cost-effective method for evaluating cardiac volumes and ejection fractions.

Its accuracy already matches that of the MRI (Magnetic resonance imaging (MRI) scan), the gold standard, so there is a significant opportunity for the unique 4D VMS+ system in the market, the firm reckons.

Also in today' statement, Ventripoint revealed it had entered into a business development contract for a term of six months.

Under the deal, which is subject to the approval of the TSX venture exchange, Ventripoint will pay the consulting fee of US$150,000  via shares at the end of the term, with the number of shares being determined by the market price at the time of issue.

On Monday, the company said that St. Michael's Hospital in Toronto had ordered its VMS Plus system to use it to assess cardiac patients

Dr Howard Leong-Poi and Dr Chi-Ming Chow are spearheading the VMS+ acquisition.

Leong-Poi is the head of the cardiology division at St. Michael's Hospital and a clinician-scientist in the Keenan Research Centre for biomedical science.

"We are very pleased to have the interest and commitment from such a high profile cardiac institution in our own backyard," said Desmond Hirson, the president of VentriPoint.

"We believe that our AI technology and product in the hands of Drs. Leong-Poi and Chow will make a valuable difference to patient outcomes."

 

Contact Giles Gwinnett at [email protected]

Follow Giles on Twitter @Gile74

Giles_55af4ddca6481.jpg


Register here to be notified of future VPT Company articles
View full VPT profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.